BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 10755535)

  • 41. Isolated pleural PTLD after cardiac transplantation.
    Lamba M; Jabi M; Padmore R; Sengar DP; Veinot JP
    Cardiovasc Pathol; 2002; 11(6):346-50. PubMed ID: 12459436
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Post-transplant lymphoproliferative disease in liver transplant recipients--Merkur University Hospital single center experience].
    Filipec-Kanizaj T; Budimir J; Colić-Cvrlje V; Kardum-Skelin I; Sustercić D; Naumovski-Mihalić S; Mrzljak A; Kolonić SO; Sobocan N; Bradić T; Dolić ZM; Kocman B; Katicić M; Zidovec-Lepej S; Vince A
    Acta Med Croatica; 2011 Sep; 65 Suppl 1():37-43. PubMed ID: 23126028
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Posttransplant lymphoproliferative disorder after liver and kidney transplant.
    Akar Özkan E; Özdemir BH; Deniz EE; Tunca MZ; Haberal M
    Exp Clin Transplant; 2014 Mar; 12 Suppl 1():142-8. PubMed ID: 24635813
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Patients at risk for development of posttransplant lymphoproliferative disorder: plasma versus peripheral blood mononuclear cells as material for quantification of Epstein-Barr viral load by using real-time quantitative polymerase chain reaction.
    Wagner HJ; Wessel M; Jabs W; Smets F; Fischer L; Offner G; Bucsky P
    Transplantation; 2001 Sep; 72(6):1012-9. PubMed ID: 11579293
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Post-transplant lymphoproliferative disorder in pediatric heart transplant recipients.
    Manlhiot C; Pollock-Barziv SM; Holmes C; Weitzman S; Allen U; Clarizia NA; Ngan BY; McCrindle BW; Dipchand AI
    J Heart Lung Transplant; 2010 Jun; 29(6):648-57. PubMed ID: 20304682
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Post-transplantation lymphoproliferative disorder in heart and kidney transplant patients: a single-center experience.
    Wasson S; Zafar MN; Best J; Reddy HK
    J Cardiovasc Pharmacol Ther; 2006 Mar; 11(1):77-83. PubMed ID: 16703222
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Epstein-Barr virus infection and altered control of apoptotic pathways in posttransplant lymphoproliferative disorders.
    Ghigna MR; Reineke T; Rincé P; Schüffler P; El Mchichi B; Fabre M; Jacquemin E; Durrbach A; Samuel D; Joab I; Guettier C; Lucioni M; Paulli M; Tinguely M; Raphael M
    Pathobiology; 2013; 80(2):53-9. PubMed ID: 22868923
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Biomarkers for PTLD diagnosis and therapies.
    Martinez OM
    Pediatr Nephrol; 2020 Jul; 35(7):1173-1181. PubMed ID: 31240394
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A single-center experience of post-transplant lymphoproliferative disorder (PTLD) cases after pediatric liver transplantation: Incidence, outcomes, and association with food allergy.
    Barış Z; Özçay F; Yılmaz Özbek Ö; Haberal N; Sarıalioğlu F; Haberal M
    Turk J Gastroenterol; 2018 May; 29(3):354-360. PubMed ID: 29755021
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Sustained Epstein-Barr virus detection in paediatric liver transplantation. Insights into the occurrence of late PTLD.
    D'Antiga L; Del Rizzo M; Mengoli C; Cillo U; Guariso G; Zancan L
    Liver Transpl; 2007 Mar; 13(3):343-8. PubMed ID: 17154402
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Targeted monitoring of patients at high risk of post-transplant lymphoproliferative disease by quantitative Epstein-Barr virus polymerase chain reaction.
    Omar H; Hägglund H; Gustafsson-Jernberg A; LeBlanc K; Mattsson J; Remberger M; Ringdén O; Sparrelid E; Sundin M; Winiarski J; Yun Z; Ljungman P
    Transpl Infect Dis; 2009 Oct; 11(5):393-9. PubMed ID: 19497070
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Posttransplant lymphoproliferative disorder associated with an Epstein-Barr-related virus in cynomolgus monkeys.
    Schmidtko J; Wang R; Wu CL; Mauiyyedi S; Harris NL; Della Pelle P; Brousaides N; Zagachin L; Ferry JA; Wang F; Kawai T; Sachs DH; Cosimi BA; Colvin RB
    Transplantation; 2002 May; 73(9):1431-9. PubMed ID: 12023621
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Clinicopathologic study of post-transplant lymphoproliferative disorders].
    Zhang YN; Zhou XG; Wang CZ; Wei P; Zhang SH; Zheng YY
    Zhonghua Bing Li Xue Za Zhi; 2006 Apr; 35(4):209-12. PubMed ID: 16776977
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Epstein-Barr virus load for early detection of lymphoproliferative disorder in pediatric renal transplant recipients.
    Ishihara M; Tanaka E; Sato T; Chikamoto H; Hisano M; Akioka Y; Dohno S; Maeda A; Hattori M; Wakiguchi H; Fujieda M
    Clin Nephrol; 2011 Jul; 76(1):40-8. PubMed ID: 21722604
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.
    Styczynski J; Gil L; Tridello G; Ljungman P; Donnelly JP; van der Velden W; Omar H; Martino R; Halkes C; Faraci M; Theunissen K; Kalwak K; Hubacek P; Sica S; Nozzoli C; Fagioli F; Matthes S; Diaz MA; Migliavacca M; Balduzzi A; Tomaszewska A; Camara Rde L; van Biezen A; Hoek J; Iacobelli S; Einsele H; Cesaro S;
    Clin Infect Dis; 2013 Sep; 57(6):794-802. PubMed ID: 23771985
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Response of elevated Epstein-Barr virus DNA levels to therapeutic changes in pediatric liver transplant patients: 56-month follow up and outcome.
    Holmes RD; Orban-Eller K; Karrer FR; Rowe DT; Narkewicz MR; Sokol RJ
    Transplantation; 2002 Aug; 74(3):367-72. PubMed ID: 12177616
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The recipient origin of posttransplant lymphoproliferative disorders in pulmonary transplant patients. A report of three cases.
    Wood BL; Sabath D; Broudy VC; Raghu G
    Cancer; 1996 Nov; 78(10):2223-8. PubMed ID: 8918418
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Post-transplant lymphoproliferative disorders. Molecular analysis of histogenesis and pathogenesis.
    Capello D; Berra E; Cerri M; Gaidano G
    Minerva Med; 2004 Feb; 95(1):53-64. PubMed ID: 15041926
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The value of prospective monitoring of Epstein-Barr virus DNA in blood samples of pediatric liver transplant recipients.
    Scheenstra R; Verschuuren EA; de Haan A; Slooff MJ; The TH; Bijleveld CM; Verkade HJ
    Transpl Infect Dis; 2004 Mar; 6(1):15-22. PubMed ID: 15225222
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Infusions of Epstein-Barr virus-specific cytotoxic T lymphocytes as post-remission therapy in high-risk post-transplant lymphoproliferative disorder patients: report of two cases.
    Kim N; Sohn HJ; Oh JH; Jeon YW; Lee HJ; Cho HI; Chung BH; Yang CW; Kim TG; Cho SG
    Int J Hematol; 2018 May; 107(5):596-603. PubMed ID: 29188583
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.